The company’s mean estimate for sales for the current quarter ending June-16 is 593.15 million by 20 analysts. The means estimate of sales for the year ending Dec-16 is 2.48 million by 22 analysts.
The mean price target for the shares of Illumina, Inc. (NASDAQ:ILMN) is at 132.00 while the highest price target suggested by the analysts is 145.00 and low price target is 115.00. The mean price target is calculated keeping in view the consensus of 20 brokerage firms.
The average estimate of EPS for the current fiscal quarter for Illumina, Inc. (NASDAQ:ILMN) stands at 593.15 while the EPS for the current year is fixed at 2.48 by 22 analysts.
The next one year’s EPS estimate is set at 4 by 24 analysts while a year ago the analysts suggested the company’s EPS at 3.38. The analysts also projected the company’s long-term growth at 15.80% for the upcoming five years.
In its latest quarter ended on 31st March 2016, Illumina, Inc. (NASDAQ:ILMN) reported earnings of $0.71. The posted earnings missed the analyst’s consensus by -$0.03 with the surprise factor of -4.10%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company’s sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
0 yorum:
Yorum Gönder